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Randomised clinical trials that exceed anticipated recruitment rates will by definition have the necessary precision to answer the
research question within the expected time, thus ensuring the timely release of data that will inform future clinical practice. In
addition, the national or international momentum generated brings with it a collective sense of achievement. Such trials, however,
may also identify logistical and scientific problems that researchers should be aware of and for which provision needs to be made. The
logistical problems relate to the rapid identification of the extra resources required to allow continued excellence in day-to-day
management and monitoring of trial governance (both in participating centres and in coordinating trials units). The scientific/clinical
problems include managing issues such as unexpected toxicities and suboptimal compliance, and the lack of time available in a rapidly
recruiting trial to address them. A related issue concerns the lack of time available to initiate substudies (e.g. biological substudies), the
relevance of which may only become apparent as the trial progresses. Many of these challenges were highlighted by recent
experience with the Cancer Research UK Taxotere as Adjuvant Chemotherapy trial.
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Historically, in the UK debate concerning clinical trial accrual has
centred on under recruitment into national randomised trials and
how we might rectify this. More recently the successful completion
of the Cancer Research UK Taxotere as Adjuvant Chemotherapy
(TACT) trial in early breast cancer has raised a new question. Are
there problems associated with large-scale trials that recruit too
quickly?
The TACT trial involved the coming together of the UK breast
cancer clinical trial community on a scale not previously seen
before. Five clinical trials units, 104 centres (including one Belgian
centre) and 220 clinicians collaborated together to address the
question of whether sequential Taxotere (docetaxel) following FEC
chemotherapy was superior to standard anthracycline chemother-
apy of similar duration (Barrett-Lee et al, 2002) (Figure 1). As a
result, 4162 patients were randomised into this trial in just 28
months. While many positives can be taken from the successful
completion of this trial, the scale and rapidity of recruitment
identified a number of logistical and clinical trial management
problems. This paper discusses these and seeks to identify
solutions that may enhance the management and governance of
future trials.
THE PROBLEMS OF FAST RECRUITING TRIALS
Logistical problems
If a large number of centres desire initiation at one time, this can
be overwhelming for trials units and lead to frustration at centres
and trials units alike. Delays are very likely to occur in ensuring the
proper process of site initiation is achieved.
If patients are entered more rapidly than was anticipated, trials
units can be overwhelmed by the rapid arrival of data. Subsequent
delays in processing case report forms (CRFs), chasing missing
data, and identifying and resolving data queries mean any
emerging problems contained within the data, for example,
treatment toxicity and/or compliance issues, are not seen and
acted upon quickly. Similarly for participating centres, if a centre’s
resource focus is dedicated to recruiting patients, it could be at the
expense of completing and returning CRFs promptly.
Scientific implications
The scientific implications are a consequence of speeding up
timelines for a trial. Many concern general issues of good trial
management practice; however, the implications are greater in a
fast recruiting trial due to the number of patients entered before a
problem can be identified and remedial action taken.
Treatment toxicity manifests itself at a time directly related to
treatment duration, for example, it can take several months for
acute toxicity associated with chemotherapy and/or radiotherapy
to manifest itself, and several years for any long-term sequelae of
treatment to arise. Toxicity issues may relate to an unexpected type
of toxicity or to an unexpectedly high rate of an anticipated
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sadverse event. If expected serious adverse events (SAEs) are
exempt from expedited reporting to the trial coordinators, as is
common in many trials these days, then such problems will only
become apparent when CRFs are finally received and processed. If
the recruitment rate is very high, however, a large number of
patients will have been recruited and more importantly treated, in
the intervening period. Similar arguments apply to issues related
to treatment compliance; recruitment continues while the exist-
ence and cause of any problem is uncovered.
Conducting a quality of life (QL) substudy within the main trial
illustrates a number of these issues. The exact sample size required
for a QL study is often not calculated with certainty at the start of a
trial and is therefore often presented as a range. The proportions of
patients completing both QL follow-up assessments and trial
treatment determines the actual sample size once the trial is
underway. If the estimated upper limit of recruitment is reached
before these determining factors can be assessed, researchers must
then either increase the sample size to account for hypothetical
noncompliance with either the treatment or the QL assessments, or
stop recruitment to the QL study and hope that any noncom-
pliance is within the bounds used to calculate the upper limit of the
original estimate.
Very rapid accrual to the main trial can also mean that late
initiation of correlative science substudies requiring fresh material
(e.g. blood) could result in the collection of fewer samples. For
example, patients entered earlier in the trial may be followed up at
an alternative hospital and gaining additional consent may be less
feasible. Furthermore, if such studies are activated, with requests
being made to all patients entered into the trial to date,
laboratories processing samples can themselves experience un-
manageable workload issues.
The typical efficacy end point of a randomised phase III trial in
nonmetastatic cancer is 5-year disease-free survival, and typically
the statistical analysis plan will define the observed number of
events expected to be observed before the trial has sufficient power
to detect reliably clinically important differences between treat-
ment groups. This number will have been devised according to
planned recruitment and event rates and will be expected to be an
average of early and late occurring events. If recruitment is swift,
the required number of events can be observed, with weighting
towards early events, before the duration of clinical follow-up is
mature enough to have sufficient weight to alter clinical practice,
irrespective of the statistical significance of the observed treatment
effect. This is a particular problem where the treatments under
investigation involve prolonged administration (e.g. endocrine
therapy in breast cancer). In metastatic disease trials, where the
end point is progression-free survival, the consequences of fast
recruitment are unlikely to be problematic since, the time taken to
observe progression is often considerably shorter than the time
required to observe or exclude relapse in the adjuvant setting.
Hence, fast recruitment will simply lead to a swifter conclusion of
the trial.
THE TACT TRIAL EXPERIENCE
The TACT trial was a phase III randomised trial in early breast
cancer comparing different chemotherapy schedules (Figure 1).
The treatments under investigation were well established in
metastatic disease and as with all chemotherapies were expected
to be associated with a degree of toxicity. The TACT trial aimed to
recruit 3340 patients in 3 years from 80 centres, with anticipated
monthly accrual peaking at 100 patients. A mid-trial protocol
amendment increased the target sample size to 4000. Actual
recruitment was 4162 patients from 104 centres over 28 months,
peaking at over 170 patients a month (Figure 2).
Logistical problems
The Clinical Trials & Statistics Unit at the Institute of Cancer
Research (ICR-CTSU) acted as the coordinating centre for TACT
(‘hub’), with four other UK trials offices acting as ‘spokes’ for
randomisation and data management on behalf of local and
regional research affiliations. Data arrived at all trials offices at a
faster rate than it could be processed. Consequently, regular
analyses of safety data on frozen data sets did not include the most
recent data, or the data accumulating while the analyses were
conducted. The Data Monitoring and Ethics Committee (DMEC)
could therefore only ever base recommendations on relatively
historical data.
Scientific implications
Arthralgia and myalgia during treatment with Taxotere emerged as
a more frequent and severe toxicity than had been anticipated.
Taxotere was administered during the second phase of chemother-
apy treatment, which began 12 weeks after randomisation. The
trial coordinator was alerted to the emerging problem by nurses
telephoning ICR-CTSU, but more than 1000 patients were
randomised before data from the first group of patients
randomised were available for review. The Chief Investigators
immediately informed all participating clinicians, and the patient
information sheet (PIS) was amended to highlight this toxicity.
or
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Docetaxel × 4 cycles 
Early invasive breast cancer completely resected
Adjuvant chemotherapy indicated 
FEC × 8 cycles 
(Control A)
or
Figure 1 TACT trial design.
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Figure 2 Target and actual accrual into the Taxotere as Adjuvant
Chemotherapy (TACT) Trial.
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sHowever, it was several weeks before the revised PIS was approved
by the Multi Research Ethics Committee (MREC), with further
delays in adopting it in some centres caused by their local ethics
procedures. As a result, many more patients were recruited before
the remedial action taken was fully implemented, with the duration
of treatment and logistical problems of data handling both
contributing to a further 6 months elapsing before the full effects
of the remedial action could be assessed.
The total duration of chemotherapy treatment in TACT was 26
weeks, the time taken for sufficient research nurses to alert the trial
coordinator to an unexpected treatment compliance profile, which
prompted a formal review of the compliance data. This revealed a
potential for suboptimal compliance to be a problem within
centres using the FEC control arm. It seemed likely that it was
caused by the way the trial and/or the treatments were being
perceived. Trial patients within those centres were often treated
alongside non-trial patients receiving a six-cycle regimen, and in
that setting commitment to completing eight cycles was challenged
for both the control and experimental arms. The Chief Investiga-
tors alerted all participating clinicians to the potential problem,
and the PIS was revised, but fully implementing it was subject to
the delays similar to those outlined above. Wording of the PIS
involved a sensitive balance of perceptions. Whilst there was
consensus that patients must be told they may withdraw from a
trial at any time without giving a reason, there was disagreement
about telling patients that trial results may be compromised if
patients withdrew for reasons other than treatment intolerability.
As a result of the time lag between randomising patients and
compliance data emerging, careful monitoring of compliance was
always historic. Had the problem persisted, the high recruitment
rate meant that accrual would have ended before further action
could be taken.
The recruitment plan for the QL Study was 500-700 patients
recruited over 2 years from 20 to 25 centres. The follow-up
assessments continued for 2 years. However, 829 patients were
entered in 1 year from 41 centres. Recruitment was suspended to
allow an evaluation of compliance with follow-up booklets and
treatment, which would determine whether to reopen the QL
Study. Full compliance was still impossible to evaluate 6 months
later, and there were, in any case, no resources available to
reactivate the QL Study. Fortunately, later data confirmed that
compliance with booklets was sufficiently high.
For the TACT correlative science studies, the first requests for
paraffin blocks were delayed by 5 months because of trials office
workload. Although there were no long-term consequences,
reference laboratories were overwhelmed by the rapid arrival of
paraffin blocks, with consequent delays in returning the first
blocks back to pathology laboratories. The collection of blood
samples for a further biological study was delayed until 5 months
before recruitment ended. For many centres, earlier patients were
being followed up elsewhere, making additional consent difficult to
obtain. This has resulted in the number collected being
approximately 40% below planned levels.
Plans for other add-on studies looking at cardiac toxicity,
ovarian function and bone density were halted when it became
clear that the scale and speed of recruitment meant these studies
would not be completed before the main trial had completed
accrual. While failure to conduct these add-on studies by no means
compromised the overall value of the main trial, a window of
opportunity was missed, and questions posed by these studies
remain unanswered.
THE POSSIBLE SOLUTIONS
The TACT trial has shown the power of collaboration. It has also
identified problems that if solved can enhance the conduct of
future large randomised clinical trials (Figure 3).
It would seem sensible to optimise, not maximise, both the
accrual and the number of participating centres. This could be
achieved by staggering initiation of trial sites and targeting sites
with known experience or expertise. Careful selection will ensure
all sites enter patients who would not otherwise be offered trial
entry, and not draw recruitment away from existing centres with
more expertise. It will also ensure adequate resources to support
the trial in terms of staff experienced in gaining informed
consent and completing CRFs, pharmacy support and R&D
infrastructure.
Most trials are resourced via project grants awarded for each
specific trial and the level of resource requested based on
anticipated recruitment rates. While extra funding, from NCRN,
for UK trial units running fast recruiting trials has been very
welcome, it has been responsive. Hence, it is still necessary to show
that a problem exists before further funding is awarded, with the
consequence that further time is needed to recruit and train staff. If
fast recruiting trials are to become more common, then additional
core funded experienced trial coordinators working flexibly across
trials, who are able to respond quickly to unexpectedly high levels
of incoming data or requirements for centre visits could overcome
this issue.
Better toxicity and adverse event reporting can be achieved by
carefully considering what information is not urgently required
and can be requested on the CRFs, and what information requires
the expedited reporting mechanism used for SAEs. Only suspected
unexpected serious adverse reactions (SUSARs) require expedited
reporting to the MHRA. Expedited reporting to trial coordinators
(trials unit and chief investigator) of some or all expected SAEs
could serve as a useful early warning mechanism for unexpected
rates of known SAEs. This will allow real-time processing of SAEs
(after clinical review) to monitor incidence (utilising formal
sequential analysis techniques), and interim safety analysis after
a minimum of a given number of patients or period of time
whichever occurs first.
Monitoring treatment compliance is dependent on the timely
collection of information at each stage of treatment and is helped if
only essential information is collected and the overcollection of
irrelevant detail avoided. Well-designed CRFs will capture essential
details at each stage of treatment (e.g. chemotherapy cycle) in a
timely fashion, thus allowing sequential monitoring of treatment
compliance for each treatment arm and each centre per calendar
period (to isolate a learning effect). However, real-time analysis
can only be carried out if participating centres meet CRF return
targets.
By identifying funding for substudies in parallel with the main
trial and ensuring that details of all substudies are included in the
final protocol and in the PIS and consent forms, they can be
launched at the outset of the trial or very shortly after. Specimen
processing procedures need to be negotiated, which are manage-
able and achieve realistic timelines so that central laboratories and
participating centres are prepared for the workload of biological
substudies. Some centres may not be able to accommodate extra
workload associated with certain substudies (e.g. QL), and this
should be considered at site selection but should not preclude a
centre from the trial, providing participation in that substudy is
optional. The complexities of running a portfolio of substudies
need to be recognised at the outset.
CONCLUSIONS
Process and governance require regular and timely input from
those overseeing a trial, that is, the trials unit, Chief Investigator
and substudy coordinators, the DMEC, the Trial Management
Group and Trial Steering Committee. Flexibility in trial-related
resources within trials units allows real-time data processing and
analysis of accumulating data. Rapid submission of amendments
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sto COREC and the MHRA, and efficient communication channels
with participating centres are both crucial.
While the experience described here relates to the conduct of a
UK trial, many of the issues raised are relevant for international
trials with complex logistics and remedial strategies. As interna-
tional collaboration increases, it is likely that the so-called ‘over-
recruiting’ trials will become more common. Requirements of such
trials need to be anticipated, dynamic management strategies and
flexible resourcing identified, thus allowing proper management of
such trials while avoiding excess resource allocation.
Fast recruiting trials bring benefits and instil huge enthusiasm;
they inspire collaboration within both trials units and participating
centres and ensure that large numbers of patients are entered into
clinical trials. This can result in the speedy conclusion of a trial
that can inform clinical practice. However, the need to ensure
adequate resources and capacity are available to manage fast
recruiting trials should not be underestimated Researchers must be
prepared to act quickly, if required, to amend the protocol or PIS.
They also need to ensure that substudies are ready from the outset.
This is simply good practice which if overlooked in a slow
Factors contributing to
rapid recruitment
Challenges raised by rapid recruitment  Possible trial management
solutions
Large number of centres: 
Main trial 
QL Study 
Biological studies
Conducting start up and other visits to centres
on time 
High volume of telephone queries 
Ensuring changes to protocol, patient
information or CRFs are instigated promptly
at all centres 
DMEC review out of date toxicity and
compliance data because of time lag between
data freeze and DMEC meeting   
Increased trial management workload 
Increased workload resulting from
approaching more pathology labs for blocks 
Limit number of active
recruiting centre 
Stagger trial initiation at
participating centres 
Suspend inactive centres
Be prepared to suspend 
recruitment for review of data 
Ensure swift receipt of CRFs  
within trials units 
 
Limit number of centres
participating in QL, but
ensure representative 
geographical spread 
Identify histology numbers
and contact details in real
time but stagger actual
requests for blocks
High recruitment rate: 
Main trial 
QL Study 
Biological studies
Evaluating levels of treatment related toxicity
and/or compliance, taking appropriate action
and ensuring measures are implemented at all
centres
Rapid implementation of revised patient
information at all centres 
Target reached before long-term compliance
 is known  
Blocks arrive all at once putting laboratories
under pressure to meet unrealistic timescales 
Fast-track MREC approval
mechanism for any protocol
/patient information sheet
revisions
As for large number of
centres
Figure 3 Trial management solutions to challenges raised by rapid recruitment.
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srecruiting trial results in frustration and inconvenience; for a fast
recruiting trial it could spell disaster.
Fast recruiting clinical trials are not a dream; they are now a
reality. They are not however Utopian, although many of the
potential pitfalls can be avoided if all involved in running a trial
plan ahead and communicate effectively. Adequate resources will
not resolve scientific consequences that are a direct result of fast
recruitment, but logistical nightmares can be avoided if the
consequences of over-recruitment are foreseen, and a plan of
action put in place in future clinical trials.
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